Development and characterization of sorafenib-loaded lipid nanocapsules for the treatment of glioblastoma

• Ngā kaituhi matua: Anne Clavreul (Author), Emilie Roger (Author), Milad Pourbaghi-Masouleh (Author), Laurent Lemaire (Author), Clément Tétaud (Author), Philippe Menei (Author)
• Hōputu: Pukapuka
• I whakaputaina: Taylor & Francis Group, 2018-01-01T00:00:00Z.
• Ngā marau: article
• Urunga tuihono: Connect to this object online.

Anticancer agents that target both tumor cells and angiogenesis are of potential interest for glioblastoma (GB) therapy. One such agent is sorafenib (SFN), a tyrosine kinase inhibitor. However, poor aqueous solubility and undesirable side effects limit its clinical application, including local treat...